Abstract：
OBJECTIVE: Ozenoxacin is a new antibiotic used to treat non-bullous impetigo. The aim of this study is to evaluate the microbiological and clinical efficacy of topical ozenoxacin 1% cream after 5-day twice-daily treatment, in pediatric patients with impetigo.
METHODS: This observational and prospective study included patients aged 6 months to 18 years, with non-bullous impetigo. Efficacy was measured using the Skin Infection Rating Scale (SIRS) and microbiological culture at the first visit (T0), at the second visit after 72 hours (T1) and after 5 days (T2). Safety and tolerability were also evaluated.
RESULTS: A total of 50 patients was enrolled. A reduction of SIRS score >10% after 72 hours of treatment was noticed in all patients, while a complete reduction was assessed after 5 days in all the population. Microbiologic success rates for ozenoxacin at T1 was 92% (four patients had original pathogens in the specimen culture from the skin area), whereas at T2, it was 100%.
CONCLUSIONS: Topical ozenoxacin has strong efficacy in treating impetigo in pediatric patients. Ozenoxacin\'s clinical and microbiological rapid onset of response led to consider this antibiotic a novel efficacy option for the treatment of impetigo.
METHODS: This observational and prospective study included patients aged 6 months to 18 years, with non-bullous impetigo. Efficacy was measured using the Skin Infection Rating Scale (SIRS) and microbiological culture at the first visit (T0), at the second visit after 72 hours (T1) and after 5 days (T2). Safety and tolerability were also evaluated.
RESULTS: A total of 50 patients was enrolled. A reduction of SIRS score >10% after 72 hours of treatment was noticed in all patients, while a complete reduction was assessed after 5 days in all the population. Microbiologic success rates for ozenoxacin at T1 was 92% (four patients had original pathogens in the specimen culture from the skin area), whereas at T2, it was 100%.
CONCLUSIONS: Topical ozenoxacin has strong efficacy in treating impetigo in pediatric patients. Ozenoxacin\'s clinical and microbiological rapid onset of response led to consider this antibiotic a novel efficacy option for the treatment of impetigo.
摘要：
目的：奥替诺沙星是一种用于治疗非大疱性脓疱病的新型抗生素。这项研究的目的是评估5天每天两次治疗后局部使用1％奥替诺沙星乳膏的微生物学和临床疗效，在小儿脓疱疮患者中。
方法：这项观察性和前瞻性研究包括6个月至18岁的患者，患有非大疱性脓疱疮。在首次就诊（T0）时，使用皮肤感染评定量表（SIRS）和微生物培养来测量疗效。在72小时后（T1）和5天后（T2）进行第二次访问。还评估了安全性和耐受性。
结果：共纳入50例患者。治疗72小时后，所有患者均发现SIRS评分降低>10%，而在所有人群中5天后评估完全减少。T1时奥替诺沙星的微生物成功率为92％（四名患者在皮肤区域的标本培养中有原始病原体），而在T2，它是100％。
结论：外用奥替诺沙星治疗小儿脓疱疮有较强疗效。奥替诺沙星的临床和微生物学反应迅速起效，因此认为这种抗生素是治疗脓疱病的新型疗效选择。
方法：这项观察性和前瞻性研究包括6个月至18岁的患者，患有非大疱性脓疱疮。在首次就诊（T0）时，使用皮肤感染评定量表（SIRS）和微生物培养来测量疗效。在72小时后（T1）和5天后（T2）进行第二次访问。还评估了安全性和耐受性。
结果：共纳入50例患者。治疗72小时后，所有患者均发现SIRS评分降低>10%，而在所有人群中5天后评估完全减少。T1时奥替诺沙星的微生物成功率为92％（四名患者在皮肤区域的标本培养中有原始病原体），而在T2，它是100％。
结论：外用奥替诺沙星治疗小儿脓疱疮有较强疗效。奥替诺沙星的临床和微生物学反应迅速起效，因此认为这种抗生素是治疗脓疱病的新型疗效选择。
